IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey and the United States. More Details
+ 1 more risk
Flawless balance sheet with weak fundamentals.
Share Price & News
How has IQ-AI's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IQAI is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 55% a week.
Volatility Over Time: IQAI's weekly volatility has increased from 31% to 55% over the past year.
7 Day Return
GB Healthcare Services
1 Year Return
GB Healthcare Services
Return vs Industry: IQAI exceeded the UK Healthcare Services industry which returned 8.3% over the past year.
Return vs Market: IQAI exceeded the UK Market which returned -10% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is IQ-AI's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StWe're Hopeful That IQ-AI (LON:IQAI) Will Use Its Cash Wisely
6 months ago | Simply Wall StDid Business Growth Power IQ-AI's (LON:IQAI) Share Price Gain of 162%?
8 months ago | Simply Wall StWhat Type Of Shareholder Owns IQ-AI Limited's (LON:IQAI)?
Is IQ-AI undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IQAI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IQAI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IQAI is unprofitable, so we can't compare its PE Ratio to the XE Healthcare Services industry average.
PE vs Market: IQAI is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IQAI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IQAI is overvalued based on its PB Ratio (15.1x) compared to the GB Healthcare Services industry average (4.7x).
How is IQ-AI forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IQ-AI has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine IQ-AI's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- IQ-AI competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has IQ-AI performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IQAI is currently unprofitable.
Growing Profit Margin: IQAI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IQAI is unprofitable, and losses have increased over the past 5 years at a rate of 30.3% per year.
Accelerating Growth: Unable to compare IQAI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IQAI is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-14.6%).
Return on Equity
High ROE: IQAI has a negative Return on Equity (-62.37%), as it is currently unprofitable.
How is IQ-AI's financial position?
Financial Position Analysis
Short Term Liabilities: IQAI's short term assets (£1.1M) exceed its short term liabilities (£257.6K).
Long Term Liabilities: IQAI has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IQAI is debt free.
Reducing Debt: IQAI currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IQAI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IQAI has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 17.5% each year.
What is IQ-AI current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IQAI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IQAI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IQAI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IQAI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IQAI's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Trevor Brown (74 yo)
Mr. Trevor Edward Brown, MBA, has been the Chief Executive Officer at Braveheart Investment Group plc since August 24, 2015 and IQ-AI Limited (formerly known as Flying Brands Limited) since February 13, 20...
CEO Compensation Analysis
Compensation vs Market: Trevor's total compensation ($USD86.66K) is below average for companies of similar size in the UK market ($USD345.93K).
Compensation vs Earnings: Trevor's compensation has been consistent with company performance over the past year.
|CEO & Director||5.75yrs||UK£65.00k||no data|
|Non-Executive Director||0.92yr||no data||5.67% |
|Non-Executive Director||3.83yrs||UK£30.00k||no data|
|Non-Executive Chairman||5yrs||UK£30.00k||no data|
Experienced Board: IQAI's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.5%.
IQ-AI Limited's company bio, employee growth, exchange listings and data sources
- Name: IQ-AI Limited
- Ticker: IQAI
- Exchange: LSE
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: UK£23.677m
- Shares outstanding: 160.52m
- Website: https://www.imagingbiometrics.com/iq-ai-ltd
Number of Employees
- IQ-AI Limited
- Grenville Street
- Forum 4
- Saint Helier
- JE4 8TQ
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IQAI||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||GBP||Jun 2017|
|FLBS.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 2017|
IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey and the United States. Its products include IB Clinic, a toolkit of post-processing software pl...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/26 19:11|
|End of Day Share Price||2020/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.